FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome (HCPLive) - Sep 25, 2026 - "The approval covers adult and pediatric patients aged ≥2 years with frequently relapsing or steroid dependent childhood onset INS who are in complete remission, with the goal of reducing the risk of relapse. It is based on the phase 3 INShore trial."
FDA approval • Immunology • Renal Disease
|